SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZBX - Genzyme Biosurgery -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (15)1/15/2002 11:50:59 AM
From: Extra Pale  Read Replies (1) | Respond to of 18
 
"GZBX has a cash burn of about 20M$ per quarter." Perhaps the $20m includes non-cash amortization of intangibles of $12m. Given the recent divestiture and reduction of 200 redundant positions last year, combined with an 18% projected revenue growth rate and gross margins in the mid 50% range - I think gzbx turns cash positive soon, depending on r&d budget. Tho I wouldn't mind if share price dropped 30% -g-.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News